Christopher Liu
Stock Analyst at Leerink Partners
(2.61)
# 2,143
Out of 4,711 analysts
5
Total ratings
50%
Success rate
32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $4.16 | +332.69% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $25.61 | +5.43% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $84.22 | -50.13% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $33.29 | -45.93% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $4.16
Upside: +332.69%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $25.61
Upside: +5.43%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $84.22
Upside: -50.13%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $33.29
Upside: -45.93%